Bodisen Biotech Appoints Global Law Firm
Reed Smith as Legal Counsel
Tuesday April 5, 9:37 am ET
NEW YORK--(BUSINESS WIRE)--April 5, 2005--Bodisen Biotech, Inc.,
(stock symbol: BBOI, website: /)
announced today that it has appointed Reed Smith (/)
as its legal counsel that will advise the company with SEC filings
and other corporate matters.
Founded in 1877, Reed Smith has 128 years of history and over
1000 lawyers worldwide. The firm is counsel to 29 of the top 30 U.S.
banks; 26 of the Fortune e-50 companies; 9 of the top 10
pharmaceutical companies; and 50 of the world's leading drug and
Ms. Qiong Wang, CEO of Bodisen, commented, "We are pleased to
have Reed Smith working with Bodisen. As we look forward to a year
of substantial growth, Reed Smith's proven track record and
expertise in mergers & acquisitions give us great confidence
that the interests of Bodisen and our shareholders will be protected
while we pursue various growth opportunities worldwide. The law
firm's strong presence in London and expertise on China may lead to
new strategic opportunities for us."
Vinay Ganga, partner at Reed Smith London, commented: "Reed Smith
is pleased to represent Bodisen, a Forbes 100 growth company in
China. I have recently twice visited Bodisen and its newly completed
state of the art manufacturing facility located in China. I was
impressed with the growth potential of the company, and the
extensive knowledge and dedication of its management. Reed Smith is
dedicated to serving the needs of growth companies such as
About Bodisen Biotech, Inc.
Utilizing proprietary technologies, Bodisen sells over 60
packaged products in 3 product categories throughout China: Organic
Compound Fertilizer; Organic Liquid Fertilizer; and Pesticides &
Insecticides. Bodisen's organic fertilizers can be absorbed by
plants within 48 hours while enriching soil conditions without the
damaging effects associated with chemical fertilizers.
Safe Harbor Statement
This press release may contain forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These statements are based
on the current expectations or beliefs of Bodisen Biotech, Inc.
management and are subject to a number of factors and uncertainties
that could cause actual results to differ materially from those
described in the forward-looking statements.
Bodisen Biotech, Inc.
Source: Bodisen Biotech, Inc.